PLx Pharma Retains Dr. Efthymios N. Deliargyris as Chief Medical Advisor
Dr. Deliargyris Brings More Than 25 Years of Expertise in Cardiovascular Medicine, Academia and the Biotech Industry
PLx Pharma Continues to
Dr. Deliargyris, an internationally-recognized expert in the field of thrombosis, brings to
“We are pleased to welcome Dr. Deliargyris to the
“I’m excited to contribute to the commercial launch of Aspertec, a novel aspirin formulation with the potential to benefit millions of patients with, or at risk for, cardiovascular disease,” stated Dr. Deliargyris. “PLxGuard’s innovative new technology is designed to provide fast, predictable antiplatelet efficacy and targeted aspirin delivery. These differentiating features of Aspertec have the potential to address the unmet medical need for an aspirin product with less clinical resistance and fewer gastrointestinal side effects. The clinical implications and competitive advantages are significant. I am looking forward to working with PLx to bring a best-in-class aspirin product to market and raise the standard of care for cardiovascular patients.”
Previously, Dr. Deliargyris held positions of increasing responsibility at The
Earlier in his career Dr. Deliargyris was a practicing interventional cardiologist both in the U.S. and
In addition to his extensive clinical background, Dr. Deliargyris is also internationally recognized for his original research in cardiovascular disease and thrombosis. He has authored more than 80 papers in the top peer reviewed journals including the
Aspertec 325 mg is an FDA-approved aspirin product being developed to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric-coated aspirin, while also reducing the adverse gastric events common in an acute setting. PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dosage form and preparing an sNDA for Aspertec 81 mg maintenance dose form.
About PLx Pharma Inc.
PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safe and effective aspirin products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients (API) to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property and risks that PLx may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect PLx’s business, financial conditions and results of operations are contained in PLx’s filings with the U.S. Securities and Exchange Commission (